favezelimab/pembrolizumab formulation
Generic: Favezelimab/Pembrolizumab Formulation
favezelimab/pembrolizumab formulation: 1 clinical trial tracked.
favezelimab/pembrolizumab formulation evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about favezelimab/pembrolizumab formulation, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Primary endpoint: Overall Survival (OS)
Interventionalopen3,500 targetStarted 2018-08Completion 2043-08782 sites · Argentina, Australia, Austria, Belgium…Merck Sharp & Dohme LLC